1.	Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: FE200486 CS31, EudraCT number: 2008-008604-40, NCT00884273
2.	Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: FE200486 CS29, EudraCT No: 2008-003931-19, NCT00801242
3.	Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: FE200486 CS28, 2008-004338-26 (EudraCT No), NCT00831233
4.	Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: FE200486 CS30, 2008-005232-33 (EudraCT No), NCT00833248
5.	A Study of Degarelix in Patients With Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: FE200486 CS37, RISPSA, NCT00928434
6.	A Trial of Degarelix in Patients With Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: FE200486 CS35, NCT00946920
7.	A Long Term Safety Study of Degarelix in Patients With Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: FE200486 CS34, EudraCT No: 2008-006827-29, NCT00967018
8.	Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia. Phase: Phase II Type: Treatment Status: Active Age: 55 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: FE 200486 CS25, EudraCT Number: 2007-003578-04, NCT00527488